Home Biosimilar Antibodies Immunology & Inflammation Interleukins Brodalumab (anti-IL17RA)
For research use only. Not for use in humans.

Brodalumab (anti-IL17RA)

Synonyms: KHK4827, AMG 827

Brodalumab (anti-IL17RA) (KHK4827, AMG 827) is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R).

Brodalumab (anti-IL17RA)

Quality Control

Batch: Purity: 99% Protein concentration: 3.01mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Brodalumab (anti-IL17RA) (KHK4827, AMG 827) is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R).
References

Product Details

CAS No. 1174395-19-7
Molecular Weight 144 kDa
Isotype Human IgG2
Source CHO Cells
Purification PBS Buffer, PH 7.4
Sterility 0.2 μM filtered
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03240809 ACTIVE_NOT_RECRUITING Psoriasis Bausch Health Americas, Inc. 2020-01-24 PHASE4
NCT06673329 RECRUITING Drug: Brodalumab Breast Cancer; Esophageal Cancer; Kidney Cancer; Lung Cancer; Thyroid Cancer; Gynecologic Cancer; Pancreatic Cancer; Stomach Cancer; Brain Tumor; Colon Cancer; Rectal Cancer; Head and Neck Cancer; Oral Cancer; Liver Cancer; Skin Cancer; Prostate Cancer; Testicular Cancer; Solid Tumor Brian Henick, MD 2025-03-11 PHASE1
NCT04306315 COMPLETED Psoriasis Vulgaris LEO Pharma 2022-07-21 PHASE4
NCT04340076 COMPLETED Drug: Secukinumab|Drug: Ixekizumab|Drug: Brodalumab|Drug: Gu Psoriasis; Psoriasis Vulgaris Radboud University Medical Center 2020-08-20 PHASE4
NCT04080635 RECRUITING Psoriasis Vulgaris University Hospital, Ghent 2018-12-14
NCT04305327 TERMINATED Drug: Brodalumab|Drug: Ustekinumab|Drug: Placebo Psoriasis LEO Pharma 2022-12-07 PHASE3

(data from https://clinicaltrials.gov, updated on 2025-09-16)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.